ES2149869T3 - Derivados de indol sustituidos por formil o ciano con actividad dopominergica. - Google Patents

Derivados de indol sustituidos por formil o ciano con actividad dopominergica.

Info

Publication number
ES2149869T3
ES2149869T3 ES94911606T ES94911606T ES2149869T3 ES 2149869 T3 ES2149869 T3 ES 2149869T3 ES 94911606 T ES94911606 T ES 94911606T ES 94911606 T ES94911606 T ES 94911606T ES 2149869 T3 ES2149869 T3 ES 2149869T3
Authority
ES
Spain
Prior art keywords
alkyl
halogen
pct
hydrogen
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94911606T
Other languages
English (en)
Inventor
Bengt Ronny Andersson
Per Arvid Emil Carlsson
Lars Olov Hansson
Clas Ake Sonesson
Nils Peter Stjernlof
Kjell Anders Ivan Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2149869T3 publication Critical patent/ES2149869T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UN COMPUESTO DE FORMULA (I) Y SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, DONDE Z ES R3 Y X E Y FORMAN (A), O X ES R3 E Y Y Z FORMAN (A), (B) O (C); R1 Y R2 SON INDEPENDIENTEMENTE HIDROGENO, ALQUIL C1-6, CICLOALQUIL C3-7, CICLOALQUIL-CH2-C3-7, FENIL (OPCIONALMENTE SUSTITUIDO CON UN HALOGENO O ALQUIL C1-6), TIOFENIL (OPCIONALMENTE SUSTITUIDO CON HALOGENO O UN ALQUIL C1-6) O UN ALQUIL FENILC1-6; R3 SON INDEPENDIENTEMENTE HIDROGENO, HALOGENO, ALQUIL-O-C1-6 O ALQUIL C1-6; R4 ES UNA UNION DE VALENCIAS, CH2 U OXIGENO; R5 Y R6 SON INDEPENDIENTEMENTE HIDROGENO, SULFURO, ALQUIL-S-C1-6, HALOGENO, CON(R3)2, COCF3, ALQUIL-CO-C1-6, FENIL-CO, OXIGENO, -COHO-CN, EXCEPTO QUE CUANDO Y Y Z FORMAN (B), R1 Y R2 SON HIDROGENO O UN ALQUIL C1-6 Y R3 ES HIDROGENO, ENTONCES AL MENOS UNO DE R5 Y R6 TIENE QUE SER DISTINTO DE HIDROGENO. ESTOS COMPUESTOS Y DERIVADOS DE LOS MISMOS, MUESTRAN POR TANTO UNA ACTIVIDAD ESTIMULANTE RECEPTORA DE DOPAMINA EN MAMIFEROS, UTIL PARA TRATAR LA HIPERPROLACTINEMIA, GALACTORREA,AMENORREA, IMPOTENCIA, PARKINSON, DIABETES, ACROMEGALIA, HIPERTENSION Y OTROS DESORDENES DEL SISTEMA NERVIOSO CENTRAL QUE RESPONDEN A LA ESTIMULACION DE RECEPTOR DE DOPAMINA.
ES94911606T 1993-03-25 1994-03-21 Derivados de indol sustituidos por formil o ciano con actividad dopominergica. Expired - Lifetime ES2149869T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3756893A 1993-03-25 1993-03-25

Publications (1)

Publication Number Publication Date
ES2149869T3 true ES2149869T3 (es) 2000-11-16

Family

ID=21895045

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94911606T Expired - Lifetime ES2149869T3 (es) 1993-03-25 1994-03-21 Derivados de indol sustituidos por formil o ciano con actividad dopominergica.

Country Status (13)

Country Link
US (1) US5639778A (es)
EP (1) EP0690843B1 (es)
JP (1) JP3298885B2 (es)
AT (1) ATE195935T1 (es)
AU (1) AU679053B2 (es)
DE (1) DE69425736T2 (es)
DK (1) DK0690843T3 (es)
ES (1) ES2149869T3 (es)
GR (1) GR3034906T3 (es)
LV (1) LV12792B (es)
NZ (1) NZ263403A (es)
PT (1) PT690843E (es)
WO (1) WO1994021608A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) * 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
KR20000016147A (ko) * 1996-05-31 2000-03-25 로렌스 티. 마이젠헬더 선택적 도파민 d3 리간드로서의 아릴 치환된 시클릭 아민
FR2763335B1 (fr) * 1997-05-16 2000-11-24 Adir Nouveaux composes heterocycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IT1292155B1 (it) * 1997-06-13 1999-01-25 Zambon Spa Derivati naftotiazolonici attivi sul recettore dopaminergico d 3
AU2002233928A1 (en) * 2000-12-18 2002-07-01 Eli Lilly And Company Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7053223B2 (en) * 2003-02-14 2006-05-30 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CN103073460B (zh) * 2004-10-14 2015-09-09 Abbvie德国有限责任两合公司 适用于治疗对于多巴胺d3受体的调节有反应的疾病的芳基磺酰基甲基或芳基磺酰胺取代的芳族化合物
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
TW201040154A (en) * 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
HRP20191283T1 (hr) 2014-01-24 2019-10-18 Turning Point Therapeutics, Inc. Diaril makrocikli kao modulatori protein kinaze
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP4397665A3 (en) 2015-07-06 2024-08-21 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
DK3325488T3 (da) 2015-07-21 2020-09-14 Turning Point Therapeutics Inc Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
TW201815799A (zh) 2016-07-28 2018-05-01 美商Ｔｐ生物醫藥公司 巨環激酶抑制劑
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018151240A1 (ja) * 2017-02-17 2018-08-23 第一三共株式会社 ３，６，７，８－テトラヒドロシクロペンタ［ｅ］インドール化合物
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
US20210087206A1 (en) * 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
CN111511746B (zh) * 2017-12-19 2024-01-09 特普医药公司 用于治疗疾病的巨环化合物
TW202220965A (zh) * 2020-08-06 2022-06-01 美商塔朵根公司 用於心理疾患或心理增強之２－胺基茚滿化合物
CN112724068A (zh) * 2020-12-30 2021-04-30 蔡桂坡 具有hdac抑制活性的吲哚类衍生物的合成方法及肿瘤应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060626A (en) * 1972-01-26 1977-11-29 Boehringer Mannheim G.M.B.H. Indole-carboxylic carbon compounds and pharmaceutical compositions containing them
DE2740836A1 (de) * 1977-09-10 1979-03-22 Troponwerke Gmbh & Co Kg Anellierte indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
CA1159459A (en) * 1980-12-11 1983-12-27 Andre A. Asselin 6,7,8,9-tetrahydro-3h-benz¬e| indolamine derivatives
US4510157A (en) * 1982-12-27 1985-04-09 Ayerst, Mckenna & Harrison, Inc. 6,7,8,9-Tetrahydro-1H-benz(g)indol-8-amine derivatives
US4470990A (en) * 1983-03-14 1984-09-11 Ayerst, Mckenna & Harrison Inc. 6,7,8,9-Tetrahydronaphtho(1,2-B)furan-8-amine derivatives and their use as dopamine receptor stimulants
FR2613365B1 (fr) * 1987-04-01 1989-07-28 Adir Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
FR2613364B1 (fr) * 1987-04-01 1989-06-09 Adir Nouvelles amines tricycliques derivees du tetrahydro-5, 6, 7, 8 naphto (2, 3b) dihydro-2, 3 furanne, et du tetrahydro-6, 7, 8, 9 5h-benzocyclohepta (2, 3b) dihydro-2, 3 furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
AU639301B2 (en) * 1990-01-11 1993-07-22 Pharmacia & Upjohn Company New centrally acting 6,7,8,9-tetrahydro-3h-benz(e)indole heterocyclics

Also Published As

Publication number Publication date
WO1994021608A1 (en) 1994-09-29
LV12792B (en) 2002-06-20
DK0690843T3 (da) 2000-11-13
DE69425736T2 (de) 2001-04-12
EP0690843B1 (en) 2000-08-30
NZ263403A (en) 1996-10-28
AU6408694A (en) 1994-10-11
US5639778A (en) 1997-06-17
DE69425736D1 (de) 2000-10-05
PT690843E (pt) 2001-01-31
JP3298885B2 (ja) 2002-07-08
JPH08508251A (ja) 1996-09-03
LV12792A (en) 2002-02-20
AU679053B2 (en) 1997-06-19
GR3034906T3 (en) 2001-02-28
ATE195935T1 (de) 2000-09-15
EP0690843A1 (en) 1996-01-10

Similar Documents

Publication Publication Date Title
ES2149869T3 (es) Derivados de indol sustituidos por formil o ciano con actividad dopominergica.
CO4340689A1 (es) Precursores activos de antagonistas de los receptores mor- folino taquiquinina
CO5070570A1 (es) DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE
DE69725113D1 (de) Azetidin- und Pyrrolidinderivate
AR247213A1 (es) Preparacion de acido 7-¡(1-carboxi-3-fenilpropil)amino¿-3,4,6,7,8,12b-octahidro-6-oxopirido ¡2,1-a¿ o hexahidro-6-oxo-1h(1,4-tiazino¡3,4-a¿¡2¿-benzazepin-4-carboxilico, agentes hipertensivos.
DK0625977T3 (da) Piperazinderivater som 5-1A-antagonister
BG108674A (bg) Пиперазинови производни с ccr1 рецепторна антагонистична активност
MY131641A (en) Indoline derivatives, process of preparation and use
IT1252227B (it) Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
DK0711291T3 (da) N-(Piperidinyl-1-alkyl)-substituerede cyclohexancarboxylsyreamider som 5-HT1A-receptorantagonister
ES2144009T3 (es) Nuevas piperazincarboxamidas.
ATE49211T1 (de) Dreizyklische oxindole als antientzuendungsmittel.
ES2081810T3 (es) Derivados de 4-fenil-4-(n-(2-fluorofenil)amido)-piperidina.
ES2102327A1 (es) Nuevos derivados de 2,2,6,6-tetrametilpiperidina para utilizarse como agentes estabilizantes para materiales organicos contra la luz, el calor, y la oxidacion. n
NZ501785A (en) 4-(3,4-dihydro-2-naphthylmethyl)- or 4-(2H-3-chromenylmethyl)-4,5-dihydro-1H-imidazole derivatives
DK109285A (da) Laegemidler paa basis af piperidinderivater, piperidinderivater ogfremgangsmaade til deres fremstilling
AR247737A1 (es) Un procedimiento para la fabricacion de compuestos.
SE8800863D0 (sv) 3-(2-haloethyl)-1,4-oxathiins and 2-(2-haloethyl)-1,4-dithiins and treatment of leukemia and tumors therewith
KR970706280A (ko) 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)
ES2014975B3 (es) Nuevas 1,4 iento para su obtencion, asi como su utilizacion como medicamentos.
CA2157586A1 (en) Indoletetralins having dopaminergic activity
ATE119883T1 (de) Thioformamidderivate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 690843

Country of ref document: ES